organization · Reporting owner
Samsara BioCapital, L.P.
Disclosed activity across 7 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.KLRS · Entity 6805 | 10% owner | May 20, 2026 | May 22, 2026 |
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | 10% owner | April 11, 2022 | April 13, 2022 |
| Neurogene Inc.NGNE · Entity 5160 | 10% owner | November 26, 2024 | November 27, 2024 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | 10% owner | October 16, 2023 | October 18, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date May 20, 2026 · Filed May 22, 2026
Jointly reported with AKKARAJU SRINIVAS, Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Samsara Opportunity Fund, L.P. | 2,224,147 |
Reported balance
After 2026-05-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-05-20 · Purchase · Acquired 244,300 · Balance 2,224,147 F1: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 10,657,028 |
Reported balance
After 2026-05-20 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-05-20 · Other · Disposed 66,906 · Balance 10,657,028 F3: Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners. F4: The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest. F5: Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital GP, LLC | 14,937 |
Reported balance
After 2026-05-20 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-05-20 · Other · Acquired 14,937 · Balance 14,937 F6: Represents receipt of shares in the distribution in kind described in footnote (3). F7: Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital Partners, L.P. | 19,408 |
Reported balance
After 2026-05-20 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-05-20 · Other · Acquired 4,471 · Balance 19,408 F6: Represents receipt of shares in the distribution in kind described in footnote (3). F8: Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction.
F2: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein.
F3: Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners.
F4: The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest.
F5: Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
F6: Represents receipt of shares in the distribution in kind described in footnote (3).
F7: Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
F8: Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
LENZ Therapeutics, Inc.
Report date April 11, 2022 · Filed April 13, 2022
Jointly reported with AKKARAJU SRINIVAS
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 8,459,314 |
Last balance in matching sequence
After 2022-04-12 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-04-11 · Purchase · Acquired 74,464 · Balance 8,109,314 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.97 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Row 2 · 2022-04-12 · Purchase · Acquired 350,000 · Balance 8,459,314 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.05 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy 436, L.P. | 37,753 |
Reported balance
Holding disclosure · report date 2022-04-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 37,753 F4: Shares are held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.97 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.05 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4: Shares are held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.
Neurogene Inc.
Report date November 26, 2024 · Filed November 27, 2024
Jointly reported with Samsara BioCapital GP, LLC, AKKARAJU SRINIVAS
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 1,717,127 |
Last balance in matching sequence
After 2024-11-26 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2024-11-26 · Purchase · Acquired 20,748 · Balance 1,689,105 F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 2 · 2024-11-26 · Purchase · Acquired 10,803 · Balance 1,699,908 F3: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 3 · 2024-11-26 · Purchase · Acquired 15,219 · Balance 1,715,127 F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 4 · 2024-11-26 · Purchase · Acquired 2,000 · Balance 1,717,127 F5: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Scholar Rock Holding Corp
Report date October 16, 2023 · Filed October 18, 2023
Jointly reported with Samsara BioCapital GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 6,788,609 |
Reported balance
After 2023-10-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-10-16 · Purchase · Acquired 2,189,781 · Balance 6,788,609 F1: Shares are held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. Dr. Akkaraju is a director of Issuer and files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. Dr. Akkaraju is a director of Issuer and files separate Section 16 reports.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CARGO Therapeutics, Inc.
Report date May 30, 2024 · Filed June 04, 2024
Jointly reported with Samsara BioCapital GP, LLC, AKKARAJU SRINIVAS
Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 4,415,689 |
Reported balance
After 2024-05-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-05-30 · Purchase · Acquired 294,000 · Balance 4,415,689 F1: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
Mineralys Therapeutics, Inc.
Report date March 13, 2025 · Filed March 18, 2025
Jointly reported with Samsara BioCapital GP, LLC
Section 16 reporting ended · disclosed 2025-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 5,674,916 |
Reported balance
After 2025-03-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-03-13 · Purchase · Acquired 600,000 · Balance 5,674,916 F1: Securities are directly held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities are directly held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.
vTv Therapeutics Inc.
Report date March 05, 2024 · Filed December 06, 2024
Jointly reported with Samsara BioCapital GP, LLC
Section 16 reporting ended · disclosed 2024-12-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 206,784 |
Reported balance
After 2024-03-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-03-05 · Other · Disposed 58,836 · Balance 206,784 F1: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F2: These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports. |
| Pre- Funded Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 | IndirectSamsara BioCapital, L.P. | 892,578 |
Reported balance
After 2024-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-05 · Grant · Acquired 58,885 · Balance 892,578 F1: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F3: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. F2: These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share.
F2: These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports.
F3: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 22, 2026 23:47 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | OtherCommon Stock | 4,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital Partners, L.P. Disclosed balance after: 19,408 F6 · kind: Represents receipt of shares in the distribution in kind described in footnote (3). F8 · ownership.nature: Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:47 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | OtherCommon Stock | 14,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital GP, LLC Disclosed balance after: 14,937 F6 · kind: Represents receipt of shares in the distribution in kind described in footnote (3). F7 · ownership.nature: Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:47 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | OtherCommon Stock | 66,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 10,657,028 F3 · kind: Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners. F4 · balance_after: The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest. F5 · ownership.nature: Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:47 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | PurchaseCommon Stock | 244,300 | $4.83 | $1,179,969.00 |
DisclosureSEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 2,224,147 F1 · kind: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| December 18, 2025 Filed Feb 18, 2026 01:15 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | PurchaseCommon Stock | 479,847 | $10.42 | $5,000,005.74 |
DisclosureSEC source: 0001231919-26-000166 · form4-02182026_010226.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,979,847 F1 · kind: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2 · balance_after: Represents the number of shares held as of the date of this filing, including the shares purchased by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") on December 22, 2025, as reported in the reporting persons' Form 4 filed with the SEC on December 22, 2025 (the "Prior Report"). The Prior Report is deemed amended hereby. F3 · ownership.nature: Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 13, 2025 Filed Mar 18, 2025 01:05 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | PurchaseCommon Stock | 600,000 | $13.50 | $8,100,000.00 |
DisclosureSEC source: 0001415889-25-008275 · form4-03182025_010343.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 5,674,916 F1 · ownership.nature: Securities are directly held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein. Read SEC document |
| February 13, 2025 Filed Feb 24, 2025 23:59 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 32,900 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000018 · wk-form4_1740441567.xml · derivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,900 Underlying: Common Stock · 32,900 shares Expires 2035-02-13 F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 21:39 UTC | Neurogene Inc. NGNE · Entity 5160 | PurchaseCommon Stock | 2,000 | $27.50 | $55,000.00 |
DisclosureSEC source: 0001415889-24-027861 · form4-11272024_091125.xml · nonDerivative · entry 4 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 1,717,127 F5 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 21:39 UTC | Neurogene Inc. NGNE · Entity 5160 | PurchaseCommon Stock | 15,219 | $26.73 | $406,803.87 |
DisclosureSEC source: 0001415889-24-027861 · form4-11272024_091125.xml · nonDerivative · entry 3 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 1,715,127 F4 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 21:39 UTC | Neurogene Inc. NGNE · Entity 5160 | PurchaseCommon Stock | 10,803 | $26.01 | $280,986.03 |
DisclosureSEC source: 0001415889-24-027861 · form4-11272024_091125.xml · nonDerivative · entry 2 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 1,699,908 F3 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 21:39 UTC | Neurogene Inc. NGNE · Entity 5160 | PurchaseCommon Stock | 20,748 | $24.91 | $516,832.68 |
DisclosureSEC source: 0001415889-24-027861 · form4-11272024_091125.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 1,689,105 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 01:45 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | PurchaseCommon Stock | 294,000 | $17.00 | $4,998,000.00 |
DisclosureSEC source: 0001415889-24-015250 · form4-06042024_010623.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 4,415,689 F1 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| May 22, 2024 Filed May 23, 2024 20:21 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 22,000 | $0.00 Strike: $12.52 | $0.00 |
DisclosureSEC source: 0001933414-24-000021 · wk-form4_1716495693.xml · derivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting. Read SEC document |
| March 05, 2024 Filed Dec 6, 2024 21:15 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantPre- Funded Warrants (Right to Buy) · Derivative | 58,885 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001415889-24-028465 · form4-12062024_041204.xml · derivative · entry 2 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Samsara BioCapital, L.P. Disclosed balance after: 892,578 Underlying: Class A Common Stock · 58,885 shares Expires not disclosed F1 · kind: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F1 · price: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F3 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. F3 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| March 05, 2024 Filed Dec 6, 2024 21:15 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | OtherClass A Common Stock | 58,836 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-028465 · form4-12062024_041204.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 206,784 F1 · kind: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F1 · price: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F2 · ownership.nature: These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 02:06 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | PurchaseCommon Stock | 555,555 | $13.50 | $7,499,992.50 |
DisclosureSEC source: 0001415889-24-003859 · form4-02152024_020259.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,074,916 F1 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its pecuniary interest therein. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:39 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | ConversionSeries A-2 convertible preferred stock · Derivative | 1,833,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055621 · doc4.xml · derivative · entry 5 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,833,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:39 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | ConversionSeries A-1 convertible preferred stock · Derivative | 884,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055621 · doc4.xml · derivative · entry 4 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 0 Underlying: Common Stock · 884,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:39 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | ConversionSeries Seed convertible preferred stock · Derivative | 663,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055621 · doc4.xml · derivative · entry 3 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 0 Underlying: Common Stock · 663,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:39 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | PurchaseCommon Stock | 666,666 | $15.00 | $9,999,990.00 |
DisclosureSEC source: 0001209191-23-055621 · doc4.xml · nonDerivative · entry 2 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 4,121,689 F2 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:39 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | ConversionCommon Stock | 3,381,323 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-055621 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 3,455,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 21:44 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | PurchaseCommon Stock | 2,189,781 | $6.85 | $14,999,999.85 |
DisclosureSEC source: 0001209191-23-053111 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 6,788,609 F1 · ownership.nature: Shares are held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. Dr. Akkaraju is a director of Issuer and files separate Section 16 reports. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:54 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | ConversionSeries B Preferred Stock · Derivative | 1,446,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-003923 · wf-form4_167658444611991.xml · derivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,446,357 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F2 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:54 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | ConversionSeries A Preferred Stock · Derivative | 2,135,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-003923 · wf-form4_167658444611991.xml · derivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,135,504 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F2 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:54 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | PurchaseCommon Stock | 937,500 | $16.00 | $15,000,000.00 |
DisclosureSEC source: 0001628280-23-003923 · wf-form4_167658444611991.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,519,361 F2 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:54 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | ConversionCommon Stock | 3,581,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-003923 · wf-form4_167658444611991.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,581,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F2 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 02:02 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 44,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001628280-23-003427 · wf-form4_167634012632329.xml · derivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2033-02-09 F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023. Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 23:40 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 350,000 | $4.08 | $1,428,000.00 |
DisclosureSEC source: 0001209191-22-024364 · doc4.xml · nonDerivative · entry 2 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 8,459,314 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.05 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 23:40 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 74,464 | $4.07 | $303,068.48 |
DisclosureSEC source: 0001209191-22-024364 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 8,109,314 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.97 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| January 24, 2022 Filed Jan 25, 2022 19:30 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 23,000 | $8.70 | $200,100.00 |
DisclosureSEC source: 0001209191-22-004735 · doc4.xml · nonDerivative · entry 2 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 8,034,850 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.67 to $8.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 19:30 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 100,000 | $8.99 | $899,000.00 |
DisclosureSEC source: 0001209191-22-004735 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 8,011,850 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.90 to $9.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 18:48 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 43,105 | $8.92 | $384,496.60 |
DisclosureSEC source: 0001209191-22-004346 · doc4.xml · nonDerivative · entry 2 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,911,850 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.83 to $8.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 18:48 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 54,565 | $9.24 | $504,180.60 |
DisclosureSEC source: 0001209191-22-004346 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,868,745 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.64 to $9.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| December 15, 2021 Filed Dec 20, 2021 18:46 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 22,329 | $10.19 | $227,532.51 |
DisclosureSEC source: 0001209191-21-070500 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,814,180 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.16 to $10.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 18:31 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 201,685 | $10.15 | $2,047,102.75 |
DisclosureSEC source: 0001209191-21-066742 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,791,851 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.15 to $10.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| October 15, 2021 Filed Oct 15, 2021 22:06 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 2,300 | $12.49 | $28,727.00 |
DisclosureSEC source: 0001209191-21-060627 · doc4.xml · nonDerivative · entry 3 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,590,166 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 22:06 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 3,100 | $12.50 | $38,750.00 |
DisclosureSEC source: 0001209191-21-060627 · doc4.xml · nonDerivative · entry 2 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,587,866 F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 22:06 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 45,400 | $13.22 | $600,188.00 |
DisclosureSEC source: 0001209191-21-060627 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,584,766 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.11 to $13.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| October 08, 2021 Filed Oct 8, 2021 21:09 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 75,000 | $13.12 | $984,000.00 |
DisclosureSEC source: 0001209191-21-060060 · doc4.xml · nonDerivative · entry 3 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,539,366 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $13.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 21:09 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 9,021 | $14.94 | $134,773.74 |
DisclosureSEC source: 0001209191-21-060060 · doc4.xml · nonDerivative · entry 2 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,464,366 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.49 to $15.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 21:09 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 61,475 | $13.83 | $850,199.25 |
DisclosureSEC source: 0001209191-21-060060 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,455,345 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.40 to $14.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 55,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · derivative · entry 8 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 22,753 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F3 · ownership.nature: Shares held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Each of 436 LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 1,802,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · derivative · entry 7 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 741,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 15,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · derivative · entry 6 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 6,167,763 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 15,000 | $17.00 | $255,000.00 |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · nonDerivative · entry 5 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 37,753 F3 · ownership.nature: Shares held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Each of 436 LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 485,000 | $17.00 | $8,245,000.00 |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · nonDerivative · entry 4 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,393,870 F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionCommon Stock | 22,753 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · nonDerivative · entry 3 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 22,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F3 · ownership.nature: Shares held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Each of 436 LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionCommon Stock | 741,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · nonDerivative · entry 2 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 6,908,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionCommon Stock | 6,167,763 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 6,167,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.